ProMetic Life Sciences Inc. (TSE:PLI) insider Martin Leclerc purchased 8,950 shares of the stock in a transaction dated Thursday, May 25th. The stock was acquired at an average cost of C$2.03 per share, for a total transaction of C$18,168.50.

Shares of ProMetic Life Sciences Inc. (TSE:PLI) traded down 0.49% during midday trading on Friday, hitting $2.02. The stock had a trading volume of 135,955 shares. The firm’s market capitalization is $1.35 billion. ProMetic Life Sciences Inc. has a 1-year low of $1.47 and a 1-year high of $3.24. The company’s 50 day moving average price is $2.09 and its 200-day moving average price is $2.21.

COPYRIGHT VIOLATION NOTICE: “Martin Leclerc Buys 8,950 Shares of ProMetic Life Sciences Inc. (PLI) Stock” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/05/26/martin-leclerc-buys-8950-shares-of-prometic-life-sciences-inc-pli-stock.html.

Several equities research analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating on shares of ProMetic Life Sciences in a research report on Wednesday. Scotiabank reaffirmed an “outperform” rating and issued a C$4.75 price target on shares of ProMetic Life Sciences in a research report on Wednesday, April 19th. Finally, TD Securities set a C$4.50 price target on ProMetic Life Sciences and gave the company a “speculative buy” rating in a research report on Monday, April 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of C$4.63.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

12 Month Chart for TSE:PLI

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.